@article{52e0500164944fb291a6fd1c5fa3c551,
title = "Macroautophagy Regulates Nuclear NOTCH1 Activity Through Multiple p62 Binding Sites",
abstract = "NOTCH1 is the prototype of the NOTCH family of single-pass transmembrane receptors and regulates many basic processes during embryonic development and human pathogenesis. In core to NOTCH1 activation are proteolytic cleavages that release its intracellular domain (NICD1), which in turn translocates to the nucleus to regulate gene transcription. Macroautophagy (hereafter autophagy) has been shown to promote the degradation of NOTCH1, but the underlying mechanisms remain elusive. Here, we show that autophagy promotes the degradation of NOTCH1 by p62-dependent binding between NICD1 and LC3, a component of the autophagosomes that execute autophagy. Strikingly, deleting any of the structural NICD1 domains fails to block the degradation of NICD1 by autophagy, and p62 binds to almost all these domains independently, indicating that p62 binds to multiple sites on NICD1 to promote its degradation. Intriguingly, inhibition of autophagy induces the accumulation of NICD1 in not only the cytoplasm but also the nucleus and increases the transcriptional activity of NICD1, and such regulation of nuclear NICD1 by autophagy is unique to NICD1 and not observed for all other NICDs (NICD2-4). Collectively, our results suggest that autophagy tightly controls nuclear NOTCH1 activity through multiple p62 binding sites, and that modulating autophagy activity may be useful for treating NOTCH1 related human diseases.",
keywords = "NOTCH1, autophagy, degradation, p62",
author = "Ting Zhang and Lixia Guo and Yuanyuan Wang and Yanan Yang",
note = "Funding Information: This work was partly supported by the NIH/NCI award CA184817, the Mayo Clinic NIH relief award CA218109-relief, the Mayo Center for Biomedical Discovery platform award, the Mayo Clinic Department of Medicine bridge fund, the Mayo Clinic Cancer Center Developmental Therapeutics program pilot awards, the Mayo Clinic start-up fund, and the Mayo Clinic Division of Pulmonary and Critical Care discretionary fund. We thank Scott Gamb and Bing Huang (Mayo Clinic TEM core facility) for technical assistance with TEM. Gifts used in this work include full length NOTCH1 cDNA from Stephen Blacklow, HA-p62 from Qing Zhong (Addgene plasmid # 28027, ref.), 3XFlagNICD1-4 from Raphael Kopan (Addgene plasmid # 20183-20186, ref.), ErbB-3-pGL3 from Frederick Domann (Addgene plasmid # 60899, ref.), and pEGFP-LC3 from Toren Finkel (Addgene plasmid # 24920, ref.). Funding Information: This work was partly supported by the NIH/NCI award CA184817, the Mayo Clinic NIH relief award CA218109-relief, the Mayo Center for Biomedical Discovery platform award, the Mayo Clinic Department of Medicine bridge fund, the Mayo Clinic Cancer Center Developmental Therapeutics program pilot awards, the Mayo Clinic start-up fund, and the Mayo Clinic Division of Pulmonary and Critical Care discretionary fund. We thank Scott Gamb and Bing Huang (Mayo Clinic TEM core facility) for technical assistance with TEM. Gifts used in this work include full length NOTCH1 cDNA from Stephen Blacklow (21), HA-p62 from Qing Zhong (Addgene plasmid # 28027, ref. 22), 3XFlagNICD1-4 from Raphael Kopan (Addgene plasmid # 20183-20186, ref. 23), ErbB-3-pGL3 from Frederick Domann (Addgene plasmid # 60899, ref. 24), and pEGFP-LC3 from Toren Finkel (Addgene plasmid # 24920, ref. 25). Publisher Copyright: {\textcopyright} 2018 International Union of Biochemistry and Molecular Biology",
year = "2018",
month = oct,
doi = "10.1002/iub.1891",
language = "English (US)",
volume = "70",
pages = "985--994",
journal = "Biochemistry and Molecular Biology International",
issn = "1521-6543",
publisher = "Wiley-Blackwell",
number = "10",
}